Acadia Pharmaceuticals Inc.

About Acadia Pharmaceuticals Inc.

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, addressing critical unmet needs. Building on this foundation of excellence, we are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we're here to be their difference.